Crohn's Disease Latest Advances

Prenatal Exposure to Acid-Suppressive Medications and Incident Risk of Inflammatory Bowel Disease in Children.

Journal: JAMA network open

Published: June 24, 2026

Correction to: Preoperative phase angle and postoperative complications in Crohn's disease patients undergoing ileocolic resection: a retrospective cohort study.

Journal: International journal of colorectal disease

Published: June 23, 2026

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: June 23, 2026

Novel mouse models for perianal fistulizing Crohn's disease reveal therapeutic value of interferon-γ antagonists.

Journal: bioRxiv : the preprint server for biology

Published: June 22, 2026

Sulfasalazine- and Cerium Ion-Loaded Polymersomes with Enhanced RONS Scavenging and Colonic Mucosal Repair Ameliorate Experimental Colitis.

Journal: Biomacromolecules

Published: June 20, 2026

Obefazimod (ABX464) for Moderate-to-Severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Journal: Expert opinion on emerging drugs

Published: June 20, 2026

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.

Journal: Minerva gastroenterology

Published: June 19, 2026

Histologic signatures as predictors of intestinal barrier impairment in inflammatory bowel disease: integration with endoscopic and molecular markers.

Journal: Journal of Crohn's & colitis

Published: June 18, 2026

Ultra-processed food intake and risk of inflammatory bowel disease in the adult population ‒ A systematic review and meta-analysis.

Journal: Revista espanola de enfermedades digestivas

Published: June 18, 2026

High thrombin activity associated with crohn's disease induces microbiota pathogenicity contributing to mucosal inflammation.

Journal: Gut microbes

Published: June 18, 2026

The Association Between Childhood Maltreatment and Adult Intestinal Disorders: A Three-Level Meta-Analysis.

Journal: Trauma, violence & abuse

Published: June 18, 2026

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.

Journal: Journal of Crohn's & colitis

Published: June 17, 2026

Crohn's Disease Latest Advances

Find the Latest Research About Crohn's Disease

Prenatal Exposure to Acid-Suppressive Medications and Incident Risk of Inflammatory Bowel Disease in Children.

Prenatal Exposure to Acid-Suppressive Medications and Incident Risk of Inflammatory Bowel Disease in Children.

Correction to: Preoperative phase angle and postoperative complications in Crohn's disease patients undergoing ileocolic resection: a retrospective cohort study.

Correction to: Preoperative phase angle and postoperative complications in Crohn's disease patients undergoing ileocolic resection: a retrospective cohort study.

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Novel mouse models for perianal fistulizing Crohn's disease reveal therapeutic value of interferon-γ antagonists.

Novel mouse models for perianal fistulizing Crohn's disease reveal therapeutic value of interferon-γ antagonists.

Sulfasalazine- and Cerium Ion-Loaded Polymersomes with Enhanced RONS Scavenging and Colonic Mucosal Repair Ameliorate Experimental Colitis.

Sulfasalazine- and Cerium Ion-Loaded Polymersomes with Enhanced RONS Scavenging and Colonic Mucosal Repair Ameliorate Experimental Colitis.

Obefazimod (ABX464) for Moderate-to-Severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Obefazimod (ABX464) for Moderate-to-Severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.

Histologic signatures as predictors of intestinal barrier impairment in inflammatory bowel disease: integration with endoscopic and molecular markers.

Histologic signatures as predictors of intestinal barrier impairment in inflammatory bowel disease: integration with endoscopic and molecular markers.

Ultra-processed food intake and risk of inflammatory bowel disease in the adult population ‒ A systematic review and meta-analysis.

Ultra-processed food intake and risk of inflammatory bowel disease in the adult population ‒ A systematic review and meta-analysis.

High thrombin activity associated with crohn's disease induces microbiota pathogenicity contributing to mucosal inflammation.

High thrombin activity associated with crohn's disease induces microbiota pathogenicity contributing to mucosal inflammation.

The Association Between Childhood Maltreatment and Adult Intestinal Disorders: A Three-Level Meta-Analysis.

The Association Between Childhood Maltreatment and Adult Intestinal Disorders: A Three-Level Meta-Analysis.

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.